<DOC>
	<DOC>NCT01627899</DOC>
	<brief_summary>Evaluation of the clinical benefits of One Touch VerioIQ system</brief_summary>
	<brief_title>One Touch VerioIQ US Clinical Outcomes Study</brief_title>
	<detailed_description>Evaluation of the clinical benefits of the One Touch VerioIQ system. The system contains pattern alert technology and comes with educational material (Pattern guide) which provides additional support and insights to patients and health care providers to help them make more informed decisions during blood glucose management.</detailed_description>
	<criteria>male or female at least 18 to 80 years old ADA guidelines for FPG and PPG appropriate A1C greater or equal to 8.0% and less than or equal to 10.5% lab A1C greater than or equal to 8.0% in the last 612mths Diagnosed with type 1 or 2 in at least last 1 year on stable dose of OADs for at least 3mths prior to screening willingness to test 7 BGM tests per day willing to remain on same therapy as baseline (MDI) for duration of study unlikely to be compliant to study procedures has or has currently used One Touch VerioIQ Is on fixed doses of insulin for MDI therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Blood glucose monitor</keyword>
	<keyword>Pattern management</keyword>
	<keyword>Pattern guide</keyword>
	<keyword>Education</keyword>
</DOC>